表紙：インターフェロン市場の2030年までの予測：製品別、用途別、エンドユーザー別、地域別の世界分析

市場調査レポート

商品コード

1383413

インターフェロン市場の2030年までの予測：製品別、用途別、エンドユーザー別、地域別の世界分析

Interferons Market Forecasts to 2030 - Global Analysis By Product, Application, End User and By Geography

出版日: 2023年11月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 597,849円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 756,315円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 914,781円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,080,450円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界のインターフェロン市場は2023年に99億5,000万米ドルを占め、予測期間中にCAGR 5.9％で成長し、2030年には148億7,000万米ドルに達すると予想されています。

腫瘍細胞は、細菌、ウイルス、真菌、他の腫瘍細胞などの病原微生物から身を守るために、インターフェロンと呼ばれるタンパク質の一種を産生または生成します。インターフェロンは、ナチュラルキラー細胞、マクロファージ、Tヘルパー細胞のような免疫原性細胞の生成をもたらす免疫反応を誘導することによって、ウイルス細胞の複製を妨害し、感染と闘う能力を有しています。

米国小児科学会が発表したデータによると、2022年3月現在、米国では100万人以上が長期的にB型肝炎に感染しており、赤ちゃんの頃にB型肝炎に感染した人は、生涯のうちに90％の確率で肝臓がんなどの重篤な慢性疾患にかかるとされています。

増加するウイルス感染

COVID-19のパンデミックによって浮き彫りになったウイルス感染症の発生率の上昇は、不可欠な抗ウイルス薬としてインターフェロンベースの治療薬に対する市場の需要を大幅に増加させる結果となっています。さらに、これらの治療薬は、B型肝炎やC型肝炎などの慢性ウイルス感染症や急性ウイルス感染症の治療にも有用です。ウイルス性疾患は世界の健康にとって深刻な脅威であり続けているため、インターフェロン治療薬は抗ウイルス薬として不可欠な存在であり続けています。

忍容性と副作用の問題

インターフェロンに基づく治療は、自己免疫反応、疲労、抑うつ、インフルエンザ様症状など、困難な副作用を引き起こすことが多いです。患者の生活の質は、これらの副作用によって深刻な影響を受ける可能性があり、服薬を中止したり、服薬に従わなかったりすることもあります。しかし、用量の調節や支持療法によって忍容性を高める取り組みにもかかわらず、これらの副作用のコントロールは、インターフェロンの治療効果を最適化するための大きな障害であり続けています。

生物学の発展

分子生物学とバイオテクノロジーの発展は、より効果的で洗練されたインターフェロンに基づく治療法を生み出すチャンスを示しています。組換えDNA技術は、抗ウイルス、腫瘍、自己免疫疾患などの場面で、副作用を減らし、有効性を高めたインターフェロン製剤の製造を可能にすることで、改良型インターフェロンの臨床的有用性を高める可能性を秘めています。さらに、次世代インターフェロン療法は、このような生物学的ブレークスルーに対応して開発されると予想されます。

新たな競合療法の出現

現在進行中の競合療法の出現は、インターフェロン市場にとって大きな脅威となっています。インターフェロンと比較すると、C型肝炎のような疾患に対するより新しく強力な抗ウイルス薬、免疫療法、標的がん治療薬は、より優れた効果とより少ない副作用を提供することが多いです。さらに、インターフェロンに基づく治療法は、これらの代替治療による深刻な脅威に直面しており、その結果、市場シェアが低下し、採用が困難になる可能性があります。

COVID-19の影響：

インターフェロン市場は、COVID-19の大流行から様々な影響を受けています。一方では、抗ウイルス治療におけるインターフェロンの潜在的な用途がパンデミックによって明るみに出たことで、COVID-19治療へのインターフェロンの使用に対する関心と研究が高まっています。さらに、これは開発努力を加速させ、臨床試験を促しました。インターフェロンの生産と流通は、パンデミックによる臨床試験、サプライチェーン、ヘルスケアシステムの混乱によって影響を受けた。COVID-19関連の問題に焦点とリソースを振り向けた結果、他のインターフェロン研究開発分野の進展が一時的に遅くなった可能性があります。

予測期間中、インターフェロンαセグメントが最大となる見込み

インターフェロンαセグメントは最大のシェアを占めると予想されています。インターフェロンαと呼ばれる関連タンパク質のファミリーは、がんや持続性ウイルス感染を含む様々な病気の治療に使用されています。インターフェロン・アルファは、その抗ウイルス性が認められています。市場の大部分は、インターフェロン・アルファ療法の確立された臨床実践に起因しています。インターフェロン・アルファは、白血病やB型肝炎、C型肝炎の主な治療薬として使用されるなど、さまざまな症状への適応性を示してきました。さらに、研究開発の継続的な取り組みが用途を広げ、インターフェロン業界における主導的地位を確保しています。

オンライン薬局セグメントは予測期間中最も高いCAGRが見込まれる

オンライン薬局分野は最も高いCAGRで成長しています。特にCOVID-19の大流行をきっかけとしたデジタル利便性への需要の高まりが、オンライン薬局サービスの爆発的な普及の主な要因となっています。オンライン薬局は、顧客が自宅に居ながらにして薬を注文したり受け取ったりできるため、従来の実店舗型薬局に代わる便利で頻繁に利用できる手頃な薬局です。さらに、オンライン薬局業界の顕著な上昇は、eコマースの継続的な成長、オンライン薬局サービスへの信頼の高まり、宅配の手軽さなど、いくつかの要因に起因しています。

最大のシェアを持つ地域

北米が最大のシェアを占めています。さまざまな医療ニーズを抱える患者人口の多さ、高度なヘルスケア・インフラ、製薬業界の繁栄、医療費の高さなどが、この市場支配の要因と考えられています。さらに、北米は医薬品産業の成長と技術革新を支える大きな力となっており、特に米国は医薬品の生産と消費の両面で主要市場として重要な役割を果たしています。

CAGRが最も高い地域：

インターフェロン市場では、アジア太平洋地域が最も高いCAGRで成長しています。この地域の人口の多さと高齢化、ヘルスケア支出の増加、ヘルスケアサービスへのアクセスの向上、より厳しいヘルスケアニーズを持つ中流階級の消費者の増加など、多くの要因が医薬品産業の急速な拡大に寄与しています。さらに、費用対効果の高さ、高度に熟練した労働力、研究開発能力の発展により、アジア太平洋地域は臨床試験と医薬品製造の中心地として台頭しつつあります。アジア太平洋地域は、医薬品を含む革新的なヘルスケアソリューションに対する需要の高まりにより、世界の医薬品市場で最も急成長しているセグメントのひとつとなり、今後も大幅かつ安定した成長が見込まれています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレーヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第9章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第10章企業プロファイル

Novartis AG
Bayer AG
Amega Biotech
Zydus Cadila
F. Hoffmann La-Roche Ltd.
Biosidus
Pfizer Inc.
Bristol-Myers Squibb Company
Amneal Pharmaceuticals LLC.
Johnson & Johnson Private Limited
Mylan N.V.
Biogen Inc.
AbbVie Inc.
Merck & Co.,Inc.
Sun Pharmaceutical Industries Ltd.
Bausch Health Companies Inc.
Aurobindo Pharma
Schering-Plough Corporation
Hikma Pharmaceuticals PLC
AOP Orphan Pharmaceuticals AG

図表

List of Tables

Table 1 Global Interferons Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Interferons Market Outlook, By Product (2021-2030) ($MN)
Table 3 Global Interferons Market Outlook, By Interferon Gamma (2021-2030) ($MN)
Table 4 Global Interferons Market Outlook, By Interferon Beta (2021-2030) ($MN)
Table 5 Global Interferons Market Outlook, By Interferon Alpha (2021-2030) ($MN)
Table 6 Global Interferons Market Outlook, By Other Products (2021-2030) ($MN)
Table 7 Global Interferons Market Outlook, By Application (2021-2030) ($MN)
Table 8 Global Interferons Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 9 Global Interferons Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
Table 10 Global Interferons Market Outlook, By Hepatitis C (2021-2030) ($MN)
Table 11 Global Interferons Market Outlook, By Hepatitis B (2021-2030) ($MN)
Table 12 Global Interferons Market Outlook, By Melanoma (2021-2030) ($MN)
Table 13 Global Interferons Market Outlook, By Leukemia (2021-2030) ($MN)
Table 14 Global Interferons Market Outlook, By AIDS (2021-2030) ($MN)
Table 15 Global Interferons Market Outlook, By Kaposi Sarcoma (2021-2030) ($MN)
Table 16 Global Interferons Market Outlook, By Renal Cell Carcinoma (2021-2030) ($MN)
Table 17 Global Interferons Market Outlook, By Chronic Granulomatous Disease (CGD) (2021-2030) ($MN)
Table 18 Global Interferons Market Outlook, By Other Applications (2021-2030) ($MN)
Table 19 Global Interferons Market Outlook, By End User (2021-2030) ($MN)
Table 20 Global Interferons Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 21 Global Interferons Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 22 Global Interferons Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 23 Global Interferons Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 24 Global Interferons Market Outlook, By Homecare (2021-2030) ($MN)
Table 25 Global Interferons Market Outlook, By Other End Users (2021-2030) ($MN)
Table 26 North America Interferons Market Outlook, By Country (2021-2030) ($MN)
Table 27 North America Interferons Market Outlook, By Product (2021-2030) ($MN)
Table 28 North America Interferons Market Outlook, By Interferon Gamma (2021-2030) ($MN)
Table 29 North America Interferons Market Outlook, By Interferon Beta (2021-2030) ($MN)
Table 30 North America Interferons Market Outlook, By Interferon Alpha (2021-2030) ($MN)
Table 31 North America Interferons Market Outlook, By Other Products (2021-2030) ($MN)
Table 32 North America Interferons Market Outlook, By Application (2021-2030) ($MN)
Table 33 North America Interferons Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 34 North America Interferons Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
Table 35 North America Interferons Market Outlook, By Hepatitis C (2021-2030) ($MN)
Table 36 North America Interferons Market Outlook, By Hepatitis B (2021-2030) ($MN)
Table 37 North America Interferons Market Outlook, By Melanoma (2021-2030) ($MN)
Table 38 North America Interferons Market Outlook, By Leukemia (2021-2030) ($MN)
Table 39 North America Interferons Market Outlook, By AIDS (2021-2030) ($MN)
Table 40 North America Interferons Market Outlook, By Kaposi Sarcoma (2021-2030) ($MN)
Table 41 North America Interferons Market Outlook, By Renal Cell Carcinoma (2021-2030) ($MN)
Table 42 North America Interferons Market Outlook, By Chronic Granulomatous Disease (CGD) (2021-2030) ($MN)
Table 43 North America Interferons Market Outlook, By Other Applications (2021-2030) ($MN)
Table 44 North America Interferons Market Outlook, By End User (2021-2030) ($MN)
Table 45 North America Interferons Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 46 North America Interferons Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 47 North America Interferons Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 48 North America Interferons Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 49 North America Interferons Market Outlook, By Homecare (2021-2030) ($MN)
Table 50 North America Interferons Market Outlook, By Other End Users (2021-2030) ($MN)
Table 51 Europe Interferons Market Outlook, By Country (2021-2030) ($MN)
Table 52 Europe Interferons Market Outlook, By Product (2021-2030) ($MN)
Table 53 Europe Interferons Market Outlook, By Interferon Gamma (2021-2030) ($MN)
Table 54 Europe Interferons Market Outlook, By Interferon Beta (2021-2030) ($MN)
Table 55 Europe Interferons Market Outlook, By Interferon Alpha (2021-2030) ($MN)
Table 56 Europe Interferons Market Outlook, By Other Products (2021-2030) ($MN)
Table 57 Europe Interferons Market Outlook, By Application (2021-2030) ($MN)
Table 58 Europe Interferons Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 59 Europe Interferons Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
Table 60 Europe Interferons Market Outlook, By Hepatitis C (2021-2030) ($MN)
Table 61 Europe Interferons Market Outlook, By Hepatitis B (2021-2030) ($MN)
Table 62 Europe Interferons Market Outlook, By Melanoma (2021-2030) ($MN)
Table 63 Europe Interferons Market Outlook, By Leukemia (2021-2030) ($MN)
Table 64 Europe Interferons Market Outlook, By AIDS (2021-2030) ($MN)
Table 65 Europe Interferons Market Outlook, By Kaposi Sarcoma (2021-2030) ($MN)
Table 66 Europe Interferons Market Outlook, By Renal Cell Carcinoma (2021-2030) ($MN)
Table 67 Europe Interferons Market Outlook, By Chronic Granulomatous Disease (CGD) (2021-2030) ($MN)
Table 68 Europe Interferons Market Outlook, By Other Applications (2021-2030) ($MN)
Table 69 Europe Interferons Market Outlook, By End User (2021-2030) ($MN)
Table 70 Europe Interferons Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 71 Europe Interferons Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 72 Europe Interferons Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 73 Europe Interferons Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 74 Europe Interferons Market Outlook, By Homecare (2021-2030) ($MN)
Table 75 Europe Interferons Market Outlook, By Other End Users (2021-2030) ($MN)
Table 76 Asia Pacific Interferons Market Outlook, By Country (2021-2030) ($MN)
Table 77 Asia Pacific Interferons Market Outlook, By Product (2021-2030) ($MN)
Table 78 Asia Pacific Interferons Market Outlook, By Interferon Gamma (2021-2030) ($MN)
Table 79 Asia Pacific Interferons Market Outlook, By Interferon Beta (2021-2030) ($MN)
Table 80 Asia Pacific Interferons Market Outlook, By Interferon Alpha (2021-2030) ($MN)
Table 81 Asia Pacific Interferons Market Outlook, By Other Products (2021-2030) ($MN)
Table 82 Asia Pacific Interferons Market Outlook, By Application (2021-2030) ($MN)
Table 83 Asia Pacific Interferons Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 84 Asia Pacific Interferons Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
Table 85 Asia Pacific Interferons Market Outlook, By Hepatitis C (2021-2030) ($MN)
Table 86 Asia Pacific Interferons Market Outlook, By Hepatitis B (2021-2030) ($MN)
Table 87 Asia Pacific Interferons Market Outlook, By Melanoma (2021-2030) ($MN)
Table 88 Asia Pacific Interferons Market Outlook, By Leukemia (2021-2030) ($MN)
Table 89 Asia Pacific Interferons Market Outlook, By AIDS (2021-2030) ($MN)
Table 90 Asia Pacific Interferons Market Outlook, By Kaposi Sarcoma (2021-2030) ($MN)
Table 91 Asia Pacific Interferons Market Outlook, By Renal Cell Carcinoma (2021-2030) ($MN)
Table 92 Asia Pacific Interferons Market Outlook, By Chronic Granulomatous Disease (CGD) (2021-2030) ($MN)
Table 93 Asia Pacific Interferons Market Outlook, By Other Applications (2021-2030) ($MN)
Table 94 Asia Pacific Interferons Market Outlook, By End User (2021-2030) ($MN)
Table 95 Asia Pacific Interferons Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 96 Asia Pacific Interferons Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 97 Asia Pacific Interferons Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 98 Asia Pacific Interferons Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 99 Asia Pacific Interferons Market Outlook, By Homecare (2021-2030) ($MN)
Table 100 Asia Pacific Interferons Market Outlook, By Other End Users (2021-2030) ($MN)
Table 101 South America Interferons Market Outlook, By Country (2021-2030) ($MN)
Table 102 South America Interferons Market Outlook, By Product (2021-2030) ($MN)
Table 103 South America Interferons Market Outlook, By Interferon Gamma (2021-2030) ($MN)
Table 104 South America Interferons Market Outlook, By Interferon Beta (2021-2030) ($MN)
Table 105 South America Interferons Market Outlook, By Interferon Alpha (2021-2030) ($MN)
Table 106 South America Interferons Market Outlook, By Other Products (2021-2030) ($MN)
Table 107 South America Interferons Market Outlook, By Application (2021-2030) ($MN)
Table 108 South America Interferons Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 109 South America Interferons Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
Table 110 South America Interferons Market Outlook, By Hepatitis C (2021-2030) ($MN)
Table 111 South America Interferons Market Outlook, By Hepatitis B (2021-2030) ($MN)
Table 112 South America Interferons Market Outlook, By Melanoma (2021-2030) ($MN)
Table 113 South America Interferons Market Outlook, By Leukemia (2021-2030) ($MN)
Table 114 South America Interferons Market Outlook, By AIDS (2021-2030) ($MN)
Table 115 South America Interferons Market Outlook, By Kaposi Sarcoma (2021-2030) ($MN)
Table 116 South America Interferons Market Outlook, By Renal Cell Carcinoma (2021-2030) ($MN)
Table 117 South America Interferons Market Outlook, By Chronic Granulomatous Disease (CGD) (2021-2030) ($MN)
Table 118 South America Interferons Market Outlook, By Other Applications (2021-2030) ($MN)
Table 119 South America Interferons Market Outlook, By End User (2021-2030) ($MN)
Table 120 South America Interferons Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 121 South America Interferons Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 122 South America Interferons Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 123 South America Interferons Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 124 South America Interferons Market Outlook, By Homecare (2021-2030) ($MN)
Table 125 South America Interferons Market Outlook, By Other End Users (2021-2030) ($MN)
Table 126 Middle East & Africa Interferons Market Outlook, By Country (2021-2030) ($MN)
Table 127 Middle East & Africa Interferons Market Outlook, By Product (2021-2030) ($MN)
Table 128 Middle East & Africa Interferons Market Outlook, By Interferon Gamma (2021-2030) ($MN)
Table 129 Middle East & Africa Interferons Market Outlook, By Interferon Beta (2021-2030) ($MN)
Table 130 Middle East & Africa Interferons Market Outlook, By Interferon Alpha (2021-2030) ($MN)
Table 131 Middle East & Africa Interferons Market Outlook, By Other Products (2021-2030) ($MN)
Table 132 Middle East & Africa Interferons Market Outlook, By Application (2021-2030) ($MN)
Table 133 Middle East & Africa Interferons Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
Table 134 Middle East & Africa Interferons Market Outlook, By Polycythemia Vera (2021-2030) ($MN)
Table 135 Middle East & Africa Interferons Market Outlook, By Hepatitis C (2021-2030) ($MN)
Table 136 Middle East & Africa Interferons Market Outlook, By Hepatitis B (2021-2030) ($MN)
Table 137 Middle East & Africa Interferons Market Outlook, By Melanoma (2021-2030) ($MN)
Table 138 Middle East & Africa Interferons Market Outlook, By Leukemia (2021-2030) ($MN)
Table 139 Middle East & Africa Interferons Market Outlook, By AIDS (2021-2030) ($MN)
Table 140 Middle East & Africa Interferons Market Outlook, By Kaposi Sarcoma (2021-2030) ($MN)
Table 141 Middle East & Africa Interferons Market Outlook, By Renal Cell Carcinoma (2021-2030) ($MN)
Table 142 Middle East & Africa Interferons Market Outlook, By Chronic Granulomatous Disease (CGD) (2021-2030) ($MN)
Table 143 Middle East & Africa Interferons Market Outlook, By Other Applications (2021-2030) ($MN)
Table 144 Middle East & Africa Interferons Market Outlook, By End User (2021-2030) ($MN)
Table 145 Middle East & Africa Interferons Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
Table 146 Middle East & Africa Interferons Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 147 Middle East & Africa Interferons Market Outlook, By Specialty Clinics (2021-2030) ($MN)
Table 148 Middle East & Africa Interferons Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 149 Middle East & Africa Interferons Market Outlook, By Homecare (2021-2030) ($MN)
Table 150 Middle East & Africa Interferons Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC24262

According to Stratistics MRC, the Global Interferons Market is accounted for $9.95 billion in 2023 and is expected to reach $14.87 billion by 2030 growing at a CAGR of 5.9% during the forecast period. Tumor cells produce or generate a type of protein called an interferon to protect them from pathogenic microbes like bacteria, viruses, fungi, and other tumor cells. They possess the ability to obstruct the replication of viral cells and combat the infection by inducing an immune response that results in the generation of immunogenic cells like natural killer cells, macrophages, and T-helper cells.

According to data published by the American Academy of Pediatrics, in March 2022, more than 1 million people in the United States have long-term hepatitis B infections, and people who are infected with hepatitis B as a baby have a 90% chance of developing serious, chronic conditions like liver cancer in their lifetime.

Market Dynamics:

Driver:

Increasing rate of viral infections

The rising incidence of viral infections, highlighted by the COVID-19 pandemic, has resulted in a significant increase in the market demand for interferon-based treatments as indispensable antiviral medications. Additionally, these treatments are useful for treating chronic viral infections such as hepatitis B and C, as well as acute viral outbreaks. Interferon treatments continue to be an essential part of the antiviral arsenal because viral diseases continue to pose a serious threat to global health.

Restraint:

Issues with tolerability and side effects

Interferon-based treatments frequently cause difficult side effects, such as autoimmune reactions, fatigue, depression, and flu-like symptoms. Patients' quality of life may be severely impacted by these side effects, which may also cause them to stop taking their medication or not comply. However, despite initiatives to increase tolerability via adjusted dosages and supportive treatment, controlling these side effects continues to be a major obstacle to optimizing the therapeutic benefit of interferons.

Opportunity:

Developments in biology

Developments in molecular biology and biotechnology present a chance to create more effective and sophisticated interferon-based treatments. Recombinant DNA technology has the potential to increase the clinical utility of modified interferons in antiviral, oncology, and autoimmune disease settings by enabling the production of these drugs with reduced side effects and increased efficacy. Moreover, next-generation interferon therapies are anticipated to be developed in response to such biological breakthroughs.

Threat:

New competing therapies in emergence

The ongoing emergence of competing therapies poses a significant threat to the interferon market. In comparison to interferons, newer and more potent antiviral medications for diseases like hepatitis C, immunotherapy's, and targeted cancer therapies frequently offer better results and fewer side effects. Additionally, interferon-based therapies are facing a serious threat from these alternative treatments, which could result in a decrease in market share and adoption difficulties.

COVID-19 Impact:

The interferons market has experienced a variety of effects from the COVID-19 pandemic. On the one hand, interferons potential use in antiviral treatments was brought to light by the pandemic, which sparked more interest in and study into their use in the treatment of COVID-19. Furthermore, this sped up development efforts and prompted clinical trials. Interferon production and distribution were impacted by the pandemic's disruption of clinical trials, supply chains, and healthcare systems. Progress in other interferon research and development areas may have temporarily slowed as a result of the focus and resources diverted to COVID-19-related problems.

The Interferon Alpha segment is expected to be the largest during the forecast period

The interferon alpha segment is anticipated to hold the largest share. A family of related proteins called interferon alpha is used to treat a variety of illnesses, including cancer and persistent viral infections. Interferon alpha is recognized for its antiviral qualities. A significant portion of the market is attributed to the established clinical practice of interferon alpha therapy. It has shown its adaptability to a variety of conditions by serving as the main treatment option for leukemia and hepatitis B and C. Furthermore, continuous research and development initiatives broaden its applications, securing its leadership position in the interferon industry.

The Online Pharmacies segment is expected to have the highest CAGR during the forecast period

The online pharmacy segment is growing at the highest CAGR. The rising demand for digital convenience, particularly in the wake of the COVID-19 pandemic, is the primary driver of the explosion in online pharmacy services. Online pharmacies are a convenient and frequently affordable substitute for traditional brick-and-mortar pharmacies because they allow customers to order and receive medications from the comfort of their homes. Moreover, the notable rise in the online pharmacy industry can be attributed to several factors, including the continuous growth of e-commerce, the growing confidence in online pharmacy services, and the ease of home delivery.

Region with largest share:

North America holds the largest market share in the market. A large patient population with a variety of medical needs, sophisticated healthcare infrastructure, a thriving pharmaceutical industry, and high healthcare costs are all considered contributing factors to this market dominance. Additionally, North America is a major force behind the growth and innovation of the pharmaceutical industry, with the United States in particular playing a crucial role as a major market for both pharmaceutical production and consumption.

Region with highest CAGR:

In the interferon market, Asia-Pacific is growing at the highest CAGR. Many factors, such as the region's large and aging population, rising healthcare expenditures, better access to healthcare services, and the rise of middle-class consumers with more demanding healthcare needs, are contributing to the pharmaceutical industry's rapid expansion. Additionally, because of its cost-effectiveness, highly skilled workforce, and developing research and development capabilities, the Asia-Pacific region is emerging as a center for clinical trials and drug manufacturing. The Asia-Pacific region is expected to experience significant and consistent growth, resulting in it becoming one of the fastest-growing segments of the global pharmaceutical market due to the increasing demand for innovative healthcare solutions, including pharmaceuticals.

Key players in the market

Some of the key players in Interferons market include: Novartis AG, Bayer AG, Amega Biotech, Zydus Cadila, F. Hoffmann La-Roche Ltd., Biosidus, Pfizer Inc., Bristol-Myers Squibb Company, Amneal Pharmaceuticals LLC., Johnson & Johnson Private Limited, Mylan N.V., Biogen Inc., AbbVie Inc., Merck & Co.,Inc., Sun Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Aurobindo Pharma, Schering-Plough Corporation, Hikma Pharmaceuticals PLC and AOP Orphan Pharmaceuticals AG .

Key Developments:

In June 2023, Novartis Enters into Agreement to Acquire Chinook Therapeutics. Chinook Therapeutics, a biopharmaceutical company, has announced that it has entered into an agreement and plan of merger with Novartis AG. As per the deal, Novartis will acquire Chinook for a total of $3.2 billion. Unanimously approved by the board of directors, the agreement could reach $3.5 billion upon the achievement of future regulatory milestones.

In May 2023, Bayer AG has entered into an agreement with Cat Creek Energy to provide it with green electricity in Idaho. Bayer has a big presence in Idaho agriculture, including seed operations in the southwest and fertilizer production in the southeast. The work with Cat Creek catapults our energy goal target fulfillments while also supporting Idaho, said Matthias Berninger, a Bayer spokesman. Financial details were not disclosed.

In November 2022, Zydus Lifesciences has entered into a Business Transfer Agreement (BTA) for purchase of one of the Business Undertakings of Watson Pharma on a going concern basis by way of slump sale, without values being assigned to individual assets and liabilities, on cash-free and debt-free basis at a lump-sum consideration of Rs. 46.77 crore, subject to certain closing date adjustments as provided in the BTA entered into between the Company and Watson, with effect from such date, and in such manner and on the terms and conditions as mentioned in the BTA.

Products Covered:

Interferon Gamma
Interferon Beta
Interferon Alpha
Other Products

Applications Covered:

Multiple Sclerosis
Polycythemia Vera
Hepatitis C
Hepatitis B
Melanoma
Leukemia
AIDS
Kaposi Sarcoma
Renal Cell Carcinoma
Chronic Granulomatous Disease (CGD)
Other Applications

End Users Covered:

Hospital Pharmacies
Retail Pharmacies
Specialty Clinics
Online Pharmacies
Homecare
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Interferons Market, By Product

5.1 Introduction
5.2 Interferon Gamma
5.3 Interferon Beta
5.4 Interferon Alpha
5.5 Other Products

6 Global Interferons Market, By Application

6.1 Introduction
6.2 Multiple Sclerosis
6.3 Polycythemia Vera
6.4 Hepatitis C
6.5 Hepatitis B
6.6 Melanoma
6.7 Leukemia
6.8 AIDS
6.9 Kaposi Sarcoma
6.10 Renal Cell Carcinoma
6.11 Chronic Granulomatous Disease (CGD)
6.12 Other Applications

7 Global Interferons Market, By End User

7.1 Introduction
7.2 Hospital Pharmacies
7.3 Retail Pharmacies
7.4 Specialty Clinics
7.5 Online Pharmacies
7.6 Homecare
7.7 Other End Users

8 Global Interferons Market, By Geography

8.1 Introduction
8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa

9 Key Developments

9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling

10.1 Novartis AG
10.2 Bayer AG
10.3 Amega Biotech
10.4 Zydus Cadila
10.5 F. Hoffmann La-Roche Ltd.
10.6 Biosidus
10.7 Pfizer Inc.
10.8 Bristol-Myers Squibb Company
10.9 Amneal Pharmaceuticals LLC.
10.10 Johnson & Johnson Private Limited
10.11 Mylan N.V.
10.12 Biogen Inc.
10.13 AbbVie Inc.
10.14 Merck & Co.,Inc.
10.15 Sun Pharmaceutical Industries Ltd.
10.16 Bausch Health Companies Inc.
10.17 Aurobindo Pharma
10.18 Schering-Plough Corporation
10.19 Hikma Pharmaceuticals PLC
10.20 AOP Orphan Pharmaceuticals AG